WO2017010533A1 - Procédé pour favoriser la production de matrice extracellulaire, procédé pour la culture de cellules et agent pour favoriser la production de matrice extracellulaire - Google Patents

Procédé pour favoriser la production de matrice extracellulaire, procédé pour la culture de cellules et agent pour favoriser la production de matrice extracellulaire Download PDF

Info

Publication number
WO2017010533A1
WO2017010533A1 PCT/JP2016/070750 JP2016070750W WO2017010533A1 WO 2017010533 A1 WO2017010533 A1 WO 2017010533A1 JP 2016070750 W JP2016070750 W JP 2016070750W WO 2017010533 A1 WO2017010533 A1 WO 2017010533A1
Authority
WO
WIPO (PCT)
Prior art keywords
extracellular matrix
cells
cultured
alicyclic structure
matrix production
Prior art date
Application number
PCT/JP2016/070750
Other languages
English (en)
Japanese (ja)
Inventor
直也 市村
孝明 平野
Original Assignee
日本ゼオン株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日本ゼオン株式会社 filed Critical 日本ゼオン株式会社
Priority to JP2017528719A priority Critical patent/JP6806058B2/ja
Publication of WO2017010533A1 publication Critical patent/WO2017010533A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L45/00—Compositions of homopolymers or copolymers of compounds having no unsaturated aliphatic radicals in side chain, and having one or more carbon-to-carbon double bonds in a carbocyclic or in a heterocyclic ring system; Compositions of derivatives of such polymers

Definitions

  • the present invention relates to a method for promoting production of extracellular matrix produced by cultured cells, and an extracellular matrix production promoter used therefor.
  • the extracellular matrix is a protein such as collagen, fibronectin, and laminin.
  • a culture container coated with collagen For example, in a culture container coated with collagen, muscle cells, hepatocytes, spinal ganglia, embryonic lung cells, schwan cells, epithelial cells (endothelium), muscle cells, nerve cells, etc. are cultured (for example, Patent Document 1).
  • a culture vessel coated with fibronectin epithelial cells, endothelial cells, muscle cells, nerve cells, cancer cells, and the like are cultured (for example, Patent Document 2).
  • a culture container coated with laminin epithelial cells, endothelial cells, nerve cells, muscle cells, hepatocytes, and the like are cultured (for example, Patent Document 3).
  • a coating reagent containing the extracellular matrix component is used, and it takes time and effort for the operation. After coating, the extracellular matrix component is applied to the vessel. It is necessary to leave the plate in a clean environment for several hours at room temperature to 37 ° C. or overnight at 2-8 ° C. until it adsorbs.
  • the coating state of the extracellular matrix may not be constant, which is one of the causes when the reproducibility of the experiment cannot be obtained. It is also conceivable to purchase and use a pre-coated culture vessel in order to avoid the coating operation of the experimental operator and to reduce the coating variation.
  • the container that showed the coating state of the pre-coated culture container itself (guaranteed to be in a good coating state) is not sold, and the experiment operator actually Compared to the case where the coating operation is performed, it is not possible to reduce the coating variation and to eliminate the concern about the reproducibility deterioration due to the coating variation.
  • the extracellular matrix is a protein component, the risk of losing biological and physiological activities due to the influence of the management environment such as temperature, time, vibration, and light during the production of the extracellular matrix. There is also. In addition, in order to confirm that the biological and physiological activities are not lost, a sampling test is performed, but a long-term test using cells such as a neurite outgrowth assay is performed. This is a factor that increases operational complexity.
  • the present invention has been made in view of the above circumstances, and by increasing the amount of extracellular matrix produced by the cells, foreign protein-producing cells can be expressed without using a culture vessel coated with the extracellular matrix. It is an object of the present invention to provide a method for promoting extracellular matrix production of cultured cells, a method for culturing cells, and an agent for promoting extracellular matrix production of cultured cells, which can increase the amount of foreign protein to be produced.
  • the present inventors can increase the amount of extracellular matrix produced by bringing the alicyclic structure-containing polymer molded body into contact with cells in culture. As a result, the present invention has been completed.
  • a method for promoting extracellular matrix production of cultured cells which comprises contacting cultured cells with an alicyclic structure-containing polymer molded product.
  • the extracellular matrix is preferably a fibrous protein, more preferably selected from the group consisting of collagen, fibronectin, elastin, and laminin, and particularly preferably laminin 511.
  • the cell cultured here is a CHO cell.
  • a method for culturing a cell wherein the cultured cell is brought into contact with a polymer molded body containing an alicyclic structure, and the cultured cell promotes extracellular matrix production.
  • the extracellular matrix production promoter of a cultured cell which consists of an alicyclic structure containing polymer molded object is provided.
  • FIG. 1 is a graph comparing the expression levels of extracellular matrix.
  • FIG. 2 is a graph comparing erythropoietin production.
  • the cells used in the present invention are not particularly limited and can be arbitrarily selected according to the purpose.
  • the cell used in the present invention may be a gene-transferred cell having a property of expressing a foreign gene by genetic manipulation. Adhesive cells are preferred because the effects of the present invention are more easily obtained.
  • the adherent cell may be an adherent cell itself or a cell derived from an adherent cell. Adhesive cells themselves are cells that can survive and proliferate by adhering to an extracellular matrix (extracellular matrix) under normal culture conditions, and are also referred to as anchorage-dependent cells.
  • Adherent cell-derived cells are those that do not adhere to the extracellular matrix by applying some external factor to the adherent cells, such as cells that have been cultivated and cultivated, and can survive and proliferate even in suspension. It is a viable and proliferative cell.
  • the adherent cells include genetically engineered host cells and virus-sensitive cells represented by CHO cells, VERO cells, NIH3T3 cells, HEK293 cells, etc. Among them, CHO cells are preferable.
  • the extracellular matrix is a substance that exists in the extracellular space, supports the living tissue, and is produced by the cells.
  • a substance include fibrous polysaccharides and complex polysaccharides such as proteoglycan in which a polysaccharide (glucosaminoglycan) and a protein are covalently bonded.
  • fibrous protein is preferable because production is promoted particularly effectively by the extracellular matrix production promoter for cultured cells of the present invention.
  • the extracellular matrix that is a fibrous protein is known as collagen, cadherin, fibronectin, laminin, vitronectin, elastin and the like. More specifically, SPONDIN 1, SPONDIN 2, extracellular matrix protein 1, extracellular matrix protein 2, extracellular matrix protein 1, EGF-containing fibulin-like extracellular matrix protein 2, elastin microfibril interfacer 1, and elastin microfibrils interfacer such 2 Examples include elastin. In the present invention, more preferred extracellular matrix includes collagen, fibronectin, laminin and elastin, with laminin 511 being particularly preferred.
  • a liquid medium When culturing cells, a liquid medium is usually used.
  • a medium having a pH buffering action having an osmotic pressure suitable for cells, containing nutrient components of cells, and not toxic to cells is used.
  • the component exhibiting pH buffering action include tris hydrochloride, various phosphates, and various carbonates.
  • the osmotic pressure of the liquid medium is usually adjusted using an aqueous solution in which the concentrations of potassium ions, sodium ions, calcium ions, glucose and the like are adjusted so as to be almost the same as the osmotic pressure of the cells.
  • aqueous solution examples include physiological saline such as phosphate buffered saline, Tris buffered saline, and HEPES buffered saline; Ringer's solution such as lactated Ringer's solution, acetated Ringer's solution, and bicarbonated Ringer's solution; It is done.
  • the nutrient component of the cell include amino acids, nucleic acids, vitamins, minerals and the like.
  • various commercial products such as RPMI-1640, HAM, ⁇ -MEM, DMEM, EMEM, F-12, F-10, and M-199 can be used.
  • An additive can also be mix
  • additives include differentiation-inducing factors such as proteins, low-molecular compounds having differentiation-inducing activity, minerals, metals, and vitamin components.
  • Differentiation inducing factors include ligands, agonists and antagonists that act on cell surface receptors; nuclear receptor ligands, agonists and antagonists; extracellular matrices such as collagen and fivenectin; parts of the extracellular matrix; Compounds that mimic extracellular matrix; components that act on proteins involved in intracellular signal transduction pathways; components that act on enzymes of primary or secondary metabolism in cells; gene of genes in intracellular nucleus or mitochondria
  • the cell culture conditions are not particularly limited, and can be appropriately determined according to the cells to be used and the purpose.
  • the cells can be cultured using a humidified thermostat having a carbon dioxide concentration of about 5% and a constant temperature in the range of 20 ° C to 37 ° C.
  • the alicyclic structure-containing polymer molded product used in the present invention is formed by molding an alicyclic structure-containing polymer into an arbitrary shape.
  • the alicyclic structure-containing polymer is a resin having an alicyclic structure in the main chain and / or side chain, and preferably contains an alicyclic structure in the main chain from the viewpoint of mechanical strength, heat resistance, and the like.
  • Examples of the alicyclic structure include a saturated cyclic hydrocarbon (cycloalkane) structure and an unsaturated cyclic hydrocarbon (cycloalkene) structure. From the viewpoint of mechanical strength, heat resistance, etc., a cycloalkane structure or a cycloalkene structure. A structure is preferable, and a structure having a cycloalkane structure is most preferable.
  • the number of carbon atoms constituting the alicyclic structure is not particularly limited, but is usually 4 to 30, preferably 5 to 20, and more preferably 5 to 15. When the number of carbon atoms constituting the alicyclic structure is within this range, mechanical strength, heat resistance, and moldability are highly balanced, which is preferable.
  • the proportion of the repeating unit having an alicyclic structure in the alicyclic structure-containing polymer may be appropriately selected according to the purpose of use, but is usually 30% by weight or more, preferably 50% by weight or more, more preferably 70% by weight. %.
  • the remainder other than the repeating unit having an alicyclic structure in the alicyclic structure-containing polymer is not particularly limited and is appropriately selected according to the purpose of use.
  • alicyclic structure-containing polymer examples include (1) norbornene polymer, (2) monocyclic olefin polymer, (3) cyclic conjugated diene polymer, and (4) vinyl alicyclic carbonization.
  • examples thereof include hydrogen polymers and hydrides of (1) to (4).
  • norbornene-based polymers and hydrides thereof are preferable from the viewpoints of heat resistance, mechanical strength, and the like.
  • Norbornene-based polymer The norbornene-based polymer is obtained by polymerizing a norbornene-based monomer that is a monomer having a norbornene skeleton, and is obtained by ring-opening polymerization or by addition polymerization. Broadly divided into things.
  • Examples of the ring-opening polymer obtained by ring-opening polymerization include ring-opening polymers of norbornene monomers, ring-opening polymers of norbornene monomers and other monomers capable of ring-opening copolymerization, and these And hydrides thereof.
  • Examples of what can be obtained by addition polymerization include addition polymers of norbornene monomers and addition polymers of norbornene monomers and other monomers copolymerizable therewith.
  • a ring-opening polymer hydride of a norbornene monomer is preferable from the viewpoint of heat resistance, mechanical strength, and the like. From the viewpoint of operability of cell culture, a norbornene monomer having no polar group is preferable. Ring-opening polymer hydrides are particularly preferred.
  • norbornene monomer examples include bicyclo [2.2.1] hept-2-ene (common name: norbornene), 5-methyl-bicyclo [2.2.1] hept-2-ene, 5,5-dimethyl. -Bicyclo [2.2.1] hept-2-ene, 5-ethyl-bicyclo [2.2.1] hept-2-ene, 5-ethylidene-bicyclo [2.2.1] hept-2-ene 5-vinyl-bicyclo [2.2.1] hept-2-ene, 5-propenylbicyclo [2.2.1] hept-2-ene, 5-methoxycarbonyl-bicyclo [2.2.1] hepta Bicyclic single units such as -2-ene, 5-cyanobicyclo [2.2.1] hept-2-ene, 5-methyl-5-methoxycarbonyl-bicyclo [2.2.1] hept-2-ene Mer; Tricyclo [4.3.0 1,6 .
  • deca-3,7-diene (common name dicyclopentadiene), 2-methyldicyclopentadiene, 2,3-dimethyldicyclopentadiene, 2,3-dihydroxydicyclopentadiene, etc. Mer; Tetracyclo [4.4.0.1 2,5 . 1 7,10 ] -3-dodecene (tetracyclododecene), tetracyclo [4.4.0.1 2,5 . 1 7,10 ] -3-dodecene, 8-methyltetracyclo [4.4.0.1 2,5 . 1 7,10 ] -3-dodecene, 8-ethyltetracyclo [4.4.0.1 2,5 .
  • dec-3-ene (common name methanotetrahydrofluorene: 1,4-methano-1,4 , 4a, 9a-tetrahydrofluorene), 1,4-methano-8-methyl-1,4,4a, 9a-tetrahydrofluorene, 1,4-methano-8-chloro-1,4,4a, 9a- And tetracyclic monomers such as tetrahydrofluorene and 1,4-methano-8-bromo-1,4,4a, 9a-tetrahydrofluorene.
  • monomers capable of ring-opening copolymerization with norbornene monomers include cyclohexene, Cycloheptene, cyclooctene, 1,4-cyclohexadiene, 1,5-cyclooctadiene, 1,5-cyclodecadiene, 1,5,9-cyclododecatriene, 1,5,9,13-cyclohexadecatetra And monocyclic cycloolefin monomers such as ene.
  • These monomers may have one or more substituents. Examples of the substituent include an alkyl group, an alkylene group, an aryl group, a silyl group, an alkoxycarbonyl group, and an alkylidene group.
  • ⁇ -olefin monomers having 2 to 20 carbon atoms such as ethylene, propylene, 1-butene, 1-pentene and 1-hexene; cyclobutene, cyclopentene, cyclohexene, cyclooctene, tetracyclo [9.2.1.0 2,10.
  • Cycloolefin monomers such as 0 3,8 ] tetradeca-3,5,7,12-tetraene (also referred to as 3a, 5,6,7a-tetrahydro-4,7-methano-1H-indene);
  • Non-conjugated diene monomers such as 4-hexadiene, 4-methyl-1,4-hexadiene, 5-methyl-1,4-hexadiene, 1,7-octadiene, and the like.
  • ⁇ -olefin monomers are preferable, and ethylene is more preferable.
  • These monomers may have one or more substituents. Examples of the substituent include an alkyl group, an alkylene group, an aryl group, a silyl group, an alkoxycarbonyl group, and an alkylidene group.
  • a ring-opening polymer of a norbornene-based monomer, or a ring-opening polymer of a norbornene-based monomer and another monomer capable of ring-opening copolymerization with a monomer component is a known ring-opening polymerization. It can be obtained by polymerization in the presence of a catalyst.
  • the ring-opening polymerization catalyst include a catalyst comprising a metal halide such as ruthenium or osmium, a nitrate or an acetylacetone compound, and a reducing agent, or a metal halide or acetylacetone such as titanium, zirconium, tungsten, or molybdenum.
  • a catalyst comprising a compound and an organoaluminum compound can be used.
  • the ring-opening polymer hydride of norbornene-based monomer is usually added to the polymerization solution of the ring-opening polymer. It can be obtained by adding a known hydrogenation catalyst containing a transition metal such as nickel or palladium to hydrogenate the carbon-carbon unsaturated bond.
  • a catalyst composed of a titanium, zirconium or vanadium compound and an organoaluminum compound can be used.
  • Monocyclic cyclic olefin polymer for example, an addition polymer of a monocyclic olefin monomer such as cyclohexene, cycloheptene, or cyclooctene can be used. it can.
  • Cyclic conjugated diene polymer As the cyclic conjugated diene polymer, for example, a polymer obtained by subjecting a cyclic conjugated diene monomer such as cyclopentadiene or cyclohexadiene to 1,2- or 1,4-addition polymerization, and The hydride can be used.
  • Vinyl alicyclic hydrocarbon polymer examples include polymers of vinyl alicyclic hydrocarbon monomers such as vinylcyclohexene and vinylcyclohexane, and hydrides thereof; And hydrides of aromatic ring portions of polymers of vinyl aromatic monomers such as styrene and ⁇ -methylstyrene.
  • the vinyl alicyclic hydrocarbon polymer may be a copolymer of these monomers and other monomers copolymerizable therewith.
  • an alicyclic structure containing polymer Although there is no special restriction
  • the glass transition temperature of the alicyclic structure-containing polymer may be appropriately selected depending on the purpose of use, but is usually 50 to 300 ° C, preferably 100 to 280 ° C, particularly preferably 115 to 250 ° C, and more preferably 130. ⁇ 200 ° C. When the glass transition temperature is within this range, heat resistance and molding processability are highly balanced and suitable. In the present invention, the glass transition temperature is measured based on JIS K7121.
  • alicyclic structure-containing polymers can be used alone or in combination of two or more.
  • a compounding agent usually used in thermoplastic resin materials for example, a soft polymer, an antioxidant, an ultraviolet absorber, a light stabilizer, a near infrared absorber, a release agent.
  • Additives such as colorants such as dyes and pigments, plasticizers, antistatic agents, and optical brighteners can be added.
  • the alicyclic structure-containing polymer may be mixed with another polymer other than the soft polymer (hereinafter simply referred to as “other polymer”).
  • the amount of the other polymer mixed with the alicyclic structure-containing polymer is usually 200 parts by weight or less, preferably 150 parts by weight or less, more preferably 100 parts by weight with respect to 100 parts by weight of the alicyclic structure-containing polymer. It is as follows. When the proportion of various compounding agents and other polymers to be blended with respect to the alicyclic structure-containing polymer is too high, the ability to enhance phosphorylation of intracellular signal transduction proteins decreases. It is preferable to mix in the range which does not impair the property.
  • the mixing method of the alicyclic structure-containing polymerization and the compounding agent or other polymer is not particularly limited as long as the compounding agent is sufficiently dispersed in the polymer. Moreover, there is no special restriction
  • a blending method for example, a method of kneading a resin in a molten state using a mixer, a uniaxial kneader, a biaxial kneader, a roll, a Brabender, an extruder, etc., after dissolving and dispersing in a suitable solvent, Examples thereof include a method of removing the solvent by a coagulation method, a casting method, or a direct drying method.
  • a biaxial kneader is used, after kneading, it is usually extruded in a rod shape in a molten state, cut into an appropriate length with a strand cutter, and pelletized in many cases.
  • molding method of an alicyclic structure containing polymer can be arbitrarily selected according to the shape of the alicyclic structure containing polymer molded object used when making it contact with a cell.
  • molding methods include injection molding, extrusion molding, cast molding, inflation molding, blow molding, vacuum molding, press molding, compression molding, rotational molding, calendar molding, and rolling molding. , Cutting molding method, spinning and the like, and these molding methods can be combined, or post-treatment such as stretching can be carried out as necessary after molding.
  • the molded product thus obtained is the extracellular matrix production promoter for cultured cells of the present invention.
  • a plate shape, a powder form, a granular form, a string form, a sheet form, and other shapes may be sufficient.
  • the surface may be flat, may have an uneven shape, or may be a hollow molded body. Different shaped bodies can be combined into another shaped body with or without an adhesive or the like.
  • culture containers such as dishes, plates, bags, tubes, scaffolds, cups, jars and fermenters; parts of culture devices such as stirring blades, stirrers, baffles, and connecting tubes; It may be a member constituting part or all of a culture instrument used for culture operation such as a pipette, a stirring element, a filter, and a cell scraper.
  • the surface of these molded bodies can be subjected to treatments generally applied to culture vessels such as plasma treatment, corona discharge treatment, ozone treatment, ultraviolet irradiation treatment, etc., but in terms of the rate of phosphorylation enhancement of ERK and AKT. Therefore, it is preferable to use without performing these treatments. Furthermore, in the present invention, it is preferable to sterilize the molded body when the molded body is brought into contact with the cultured cells.
  • heating methods such as the high-pressure steam method and dry heat method; radiation methods that irradiate radiation such as ⁇ rays and electron beams; irradiation methods that irradiate high frequencies; ethylene oxide gas (EOG)
  • EOG ethylene oxide gas
  • a gas method in which a gas is brought into contact with each other it can be selected according to the shape of the molded body and the cells to be used.
  • a gas method in which a gas such as ethylene oxide gas is brought into contact is preferred because of its high phosphorylation enhancing activity.
  • the method of bringing the cultured cell into contact with the alicyclic structure-containing polymer molded body that is the extracellular matrix production promoter of the cultured cell of the present invention may be any method depending on the shape of the extracellular matrix production promoter of the cultured cell. Adopt it.
  • a method of culturing cells in a medium mixed with an alicyclic structure-containing polymer molded body that is an extracellular matrix production promoter for cultured cells; cells in a culture vessel molded using the alicyclic structure-containing polymer A method of culturing using a culture device molded using an alicyclic structure-containing polymer, and the like, and these can also be combined.
  • the contact temperature between the cultured cell and the alicyclic structure-containing polymer molded product is not particularly limited as long as the cell can grow.
  • Example 1 2 ml of medium was put into the 790R dish obtained in Production Example 1, CHO cells were seeded at a cell density of 1.25 ⁇ 10 4 cells / cm 2 , and a CO 2 incubator set at a temperature of 37 ° C. and a CO 2 concentration of 5%. After culturing for 8 days, the gene expression level of the extracellular matrix was analyzed by the method described later.
  • Example 1 Example 1 except that the culture vessel was replaced with the polystyrene dish [Falcon (registered trademark) dish (Becton Dickinson, Model 353001)] instead of the 790R dish obtained in Production Example 1. Culture was performed in the same manner, and the amount of extracellular matrix expression was analyzed.
  • RNA sequence analysis of about 100 bases in length was performed to obtain DNA sequence data.
  • a gene mapping process is performed to obtain the number of reads that is the number of reads of the DNA sequence for a specific gene, and the genes of the extracellular matrix are used with cells cultured in a 790R dish.
  • the number of leads analyzed was compared with the number of leads analyzed using cells cultured in polystyrene dishes.
  • FIG. 1 shows the relative value of the extracellular matrix expression level when a 790R dish is used, where the expression level of each extracellular matrix is 1 when a polystyrene dish is used.
  • Plasmid pLXRN-EPO was constructed by inserting the EPO gene sequence into the expression gene insertion site of vector pLXRN (manufactured by Chlontech) containing a gene resistant to antibiotic G418. did. The EPO gene in the constructed plasmid was confirmed by analyzing its base sequence. Next, virus particles containing the EPO gene were prepared by transducing the constructed plasmid pLXRN-EPO and the plasmid pVSV-G (Clontech) into package cells GP293T cells (Clontech). In addition, Lipofectamine (manufactured by Invitrogen) was used as a gene introduction reagent for the introduction of plasmid pLXRN-EPO into cells, and the gene introduction was performed according to the manufacturer's manual.
  • the GP293T cells subjected to the gene transfer operation are cultured, the culture supernatant is removed, filtered, and 8 ⁇ g / ml polybrene (manufactured by Santacruz) is added to the culture containing virus particles retaining the EPO gene.
  • a clear sample was prepared.
  • the virus retaining the EPO gene The particles were infected with CHO cells. After 8 hours of incubation, the culture medium for CHO cells was changed to a culture operation for CHO cells producing recombinant EPO.
  • Viral infection was confirmed by genomic PCR as follows. First, using Instagene (manufactured by BioRad), the genome was extracted from the infected CHO cells, and it was confirmed by PCR that the pLXRN-EPO sequence was introduced into the genome. Primers used for PCR were pLXRN-seq-F (5′-CGCCCTCCGTCTGAATTTT) and pLXRN-seq-R (TCCCTATGCAAAAGCGAAAC). In order to select CHO cells infected with the virus and having the EPO gene incorporated in the genome, antibiotic G418 is added to the medium, maintained in culture, and drug selection is made for antibiotic G418-resistant CHO cells. Recombinant CHO cells with the ability were selected.
  • Example 2 Using the 790R dish obtained in Production Example 1 as the culture container and Ham medium containing 10% fetal calf serum as the liquid medium, the recombinant CHO cells selected in Production Example 2 are 1.25 ⁇ 10 6. The cells were seeded at 4 cells / cm 2 and cultured for 17 days under a condition of 37 ° C. in a 5% CO 2 atmosphere. At 11 days in the middle of the culture, the volume of the medium liquid volume due to the transpiration of water was reduced during the culture. Therefore, in order to maintain the medium liquid volume, a medium having the same volume as the liquid volume decreased by the transpiration was added. Using the medium on the 17th day of culture, the amount of active EPO was measured by ELISA (human EPO Platinum ELISA manufactured by eBioscience) to determine the amount of EPO produced per unit culture area.
  • ELISA human EPO Platinum ELISA manufactured by eBioscience
  • Example 1 In Example 1, instead of the 790R dish, a polystyrene dish (Falcon registered trademark) dish (Becton Dickinson, Model No. 353001)), and polystyrene dish, gelatin, fibronectin, collagen 1, collagen 4, Dish coated with laminin and poly-D-lysine (manufactured by Becton Dickinson, Biocoat Dish Gelatin coated product: Product No. 345652, Fibronectin coated product: Product No. 354402, Collagen I coated product: Product No. 354400, Collagen IV coated product: Product No. 354428 , Laminin coated product: product number 354404, poly-D-lysine (PDL) coated product: product number 354413). It was measured quantity to obtain the EPO production per unit culture area. The results of Example 2 and Comparative Examples 2 to 7 are shown in FIG.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne : un procédé pour favoriser la production de matrice extracellulaire dans des cellules en culture, le procédé étant caractérisé par le fait d'amener des cellules qui sont en cours de culture en contact avec un moulage polymère contenant une structure alicyclique ; un procédé de culture de cellules, le procédé étant caractérisé par le fait d'amener des cellules qui sont en cours de culture en contact avec un moulage polymère contenant une structure alicyclique et de favoriser la production de matrice extracellulaire par les cellules en culture ; et un agent pour favoriser la production de matrice extracellulaire dans des cellules en culture, l'agent étant composé par un moulage polymère contenant une structure alicyclique. Selon la présente invention, l'augmentation de la quantité de matrice extracellulaire produite par des cellules permet d'augmenter la quantité de protéines exprimées par des cellules de production de protéines étrangères sans utiliser de récipient de culture revêtu d'une matrice extracellulaire.
PCT/JP2016/070750 2015-07-16 2016-07-13 Procédé pour favoriser la production de matrice extracellulaire, procédé pour la culture de cellules et agent pour favoriser la production de matrice extracellulaire WO2017010533A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017528719A JP6806058B2 (ja) 2015-07-16 2016-07-13 細胞外マトリックス産生促進方法、細胞の培養方法、及び細胞外マトリックス産生促進剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015-142338 2015-07-16
JP2015142338 2015-07-16

Publications (1)

Publication Number Publication Date
WO2017010533A1 true WO2017010533A1 (fr) 2017-01-19

Family

ID=57757525

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/070750 WO2017010533A1 (fr) 2015-07-16 2016-07-13 Procédé pour favoriser la production de matrice extracellulaire, procédé pour la culture de cellules et agent pour favoriser la production de matrice extracellulaire

Country Status (2)

Country Link
JP (1) JP6806058B2 (fr)
WO (1) WO2017010533A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3859005A4 (fr) * 2018-09-28 2022-06-29 Zeon Corporation Procédé d'évaluation de cardiotoxicité

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023771A1 (fr) * 2006-08-23 2008-02-28 Takara Bio Inc. RÉcipient DE CULTURE, ET PROCÉDÉ D'INTRODUCTION DE GÈNE ET PROCÉDÉ DE CULTURE CELLULairE UTILISANT LE RÉcipient
JP2009106160A (ja) * 2007-10-26 2009-05-21 Nipro Corp 細胞培養容器及び細胞培養方法
JP2010032487A (ja) * 2008-06-26 2010-02-12 Olympus Corp 解析用容器及び生化学的解析方法
JP2015073442A (ja) * 2013-10-06 2015-04-20 株式会社セレックス Ｎｋ細胞培養容器及びｎｋ細胞培養方法
WO2015199118A1 (fr) * 2014-06-26 2015-12-30 日本ゼオン株式会社 Procédé pour favoriser la phosphorylation d'erk ou d'akt dans une cellule cultivée, procédé de culture cellulaire et promoteur de phosphorylation
WO2015199119A1 (fr) * 2014-06-26 2015-12-30 日本ゼオン株式会社 Procédé de culture de cellules adhérentes, récipient de culture et procédé de production de protéines
WO2015199117A1 (fr) * 2014-06-26 2015-12-30 日本ゼオン株式会社 Procédé pour promouvoir la différenciation de cellules en culture et promoteur de différenciation de cellules en culture

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011050295A (ja) * 2009-09-01 2011-03-17 Scivax Kk 細胞培養構造体、細胞培養容器及びこれらの製造方法
JP3191179U (ja) * 2014-03-25 2014-06-12 株式会社精工技研 培養容器

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023771A1 (fr) * 2006-08-23 2008-02-28 Takara Bio Inc. RÉcipient DE CULTURE, ET PROCÉDÉ D'INTRODUCTION DE GÈNE ET PROCÉDÉ DE CULTURE CELLULairE UTILISANT LE RÉcipient
JP2009106160A (ja) * 2007-10-26 2009-05-21 Nipro Corp 細胞培養容器及び細胞培養方法
JP2010032487A (ja) * 2008-06-26 2010-02-12 Olympus Corp 解析用容器及び生化学的解析方法
JP2015073442A (ja) * 2013-10-06 2015-04-20 株式会社セレックス Ｎｋ細胞培養容器及びｎｋ細胞培養方法
WO2015199118A1 (fr) * 2014-06-26 2015-12-30 日本ゼオン株式会社 Procédé pour favoriser la phosphorylation d'erk ou d'akt dans une cellule cultivée, procédé de culture cellulaire et promoteur de phosphorylation
WO2015199119A1 (fr) * 2014-06-26 2015-12-30 日本ゼオン株式会社 Procédé de culture de cellules adhérentes, récipient de culture et procédé de production de protéines
WO2015199117A1 (fr) * 2014-06-26 2015-12-30 日本ゼオン株式会社 Procédé pour promouvoir la différenciation de cellules en culture et promoteur de différenciation de cellules en culture

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3859005A4 (fr) * 2018-09-28 2022-06-29 Zeon Corporation Procédé d'évaluation de cardiotoxicité

Also Published As

Publication number Publication date
JP6806058B2 (ja) 2021-01-06
JPWO2017010533A1 (ja) 2018-04-26

Similar Documents

Publication Publication Date Title
JP5867667B1 (ja) 接着型細胞の培養方法、培養容器およびタンパク質の産生方法
JP6720867B2 (ja) 培養表皮細胞の分化促進方法および培養表皮細胞分化促進剤
JP2018201403A (ja) 幹細胞の培養方法
WO2017010533A1 (fr) Procédé pour favoriser la production de matrice extracellulaire, procédé pour la culture de cellules et agent pour favoriser la production de matrice extracellulaire
JP5958658B2 (ja) 培養細胞内のｅｒｋまたはａｋｔのリン酸化亢進方法、細胞の培養方法、およびリン酸化亢進剤
JP6954121B2 (ja) 培養細胞の分化促進方法及び培養細胞分化促進剤
JP6716887B2 (ja) 接着型細胞の培養方法、及びタンパク質の産生方法
JP6988480B2 (ja) 浮遊培養馴化接着型細胞の調製方法、接着型上皮細胞の上皮間葉転換誘導方法、及びそれらの利用
JP6973082B2 (ja) 接着型細胞の培養方法
JP2019146492A (ja) 人工多能性幹細胞の分化誘導方法
JP7268439B2 (ja) 多能性幹細胞の分化誘導方法
TW201702370A (zh) 貼附型細胞的培養方法、培養容器及蛋白質的產生方法
WO2022163653A1 (fr) Vecteur, cellule recombinée de vertébré dans laquelle est introduit le vecteur, procédé pour sa production et procédé pour la production de la protéine cible

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16824513

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017528719

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16824513

Country of ref document: EP

Kind code of ref document: A1